These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

392 related items for PubMed ID: 23278995

  • 41. Estimating the potential cost of a high dose immune tolerance induction (ITI) therapy relative to the cost of a combined therapy of a low dose ITI therapy with bypassing agent prophylaxis.
    Kenet G, Oladapo A, Epstein JD, Thompson C, Novack A, Nugent DJ.
    Haemophilia; 2017 Sep; 23(5):e394-e402. PubMed ID: 28641362
    [Abstract] [Full Text] [Related]

  • 42. Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success.
    Mariani G, Kroner B, Immune Tolerance Study Group (ITSG).
    Haematologica; 2001 Nov; 86(11):1186-93. PubMed ID: 11694405
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Factor VIII inhibitors in patients with hemophilia A: epidemiology of inhibitor development and induction of immune tolerance for factor VIII.
    Kreuz W, Becker S, Lenz E, Martinez-Saguer I, Escuriola-Ettingshausen C, Funk M, Ehrenforth S, Auerswald G, Kornhuber B.
    Semin Thromb Hemost; 1995 Nov; 21(4):382-9. PubMed ID: 8747701
    [Abstract] [Full Text] [Related]

  • 46. IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A.
    van Helden PM, van den Berg HM, Gouw SC, Kaijen PH, Zuurveld MG, Mauser-Bunschoten EP, Aalberse RC, Vidarsson G, Voorberg J.
    Br J Haematol; 2008 Aug; 142(4):644-52. PubMed ID: 18510679
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. [Immune tolerance induction with high-dose FVIII and pulsed intravenous immunoglobulin].
    Stiefel M, Pinkwart C, Haase R, Merkel N, Forsberg D, Mauz-Körholz C.
    Hamostaseologie; 2010 Nov; 30 Suppl 1():S119-21. PubMed ID: 21042665
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Understanding FVIII/VWF complex--report from a symposium of XXIX WFH meeting 2010.
    Gringeri A, Ofosu FA, Grancha S, Oldenburg J, Ewing NP, Federici AB.
    Haemophilia; 2012 May; 18(3):469-75. PubMed ID: 21943193
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Challenges of the management of severe hemophilia A with inhibitors: two case reports emphasizing the potential interest of a high-purity human Factor VIII/von Willebrand factor concentrate and individually tailored prophylaxis guided by thrombin-generation test.
    Mathieu S, Crampe C, Dargaud Y, Lavigne-Lissalde G, Escuriola-Ettingshausen C, Tardy B, Meley R, Thouvenin S, Stephan JL, Berger C.
    Blood Coagul Fibrinolysis; 2015 Dec; 26(8):940-5. PubMed ID: 26517064
    [Abstract] [Full Text] [Related]

  • 53. Successful immune tolerance induction with low-dose coagulation factor VIII in a patient with hemophilia A from a developing country.
    Ay Y, Ersin T, Yesim O, Hilkay KT, Dilek I, Gulcihan O, Ahmet K.
    Blood Coagul Fibrinolysis; 2016 Sep; 27(6):729-31. PubMed ID: 26484639
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. VWF/FVIII complex and the management of patient with inhibitors: from laboratory to clinical practice.
    Berntorp E.
    Haemophilia; 2007 Dec; 13 Suppl 5():69-72. PubMed ID: 18078401
    [Abstract] [Full Text] [Related]

  • 58. Induction of immune tolerance, the future of the Registry.
    Ewing NP.
    Vox Sang; 1996 Dec; 70 Suppl 1():47-51. PubMed ID: 8869469
    [Abstract] [Full Text] [Related]

  • 59. Long-term outcome of haemophilia A patients after successful immune tolerance induction therapy using a single plasma-derived FVIII/VWF product: the long-term ITI study.
    Jiménez-Yuste V, Oldenburg J, Rangarajan S, Peiró-Jordán R, Santagostino E.
    Haemophilia; 2016 Nov; 22(6):859-865. PubMed ID: 27329267
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.